Concepedia

Author

David R. Gandara

University of California, DavisORCID

Also Known As

Baudelet, Christine, Crowley, John, D Follette, D GANDARA, D Gandara, D R Gandara, D. Gandara, D. R. Gandara, D.R Gandara, D.R. Gandara

1.1K

Publications

54.3K

Citations

99

H-Index

179

Concepts

All Affiliations

University of California, DavisUC Davis Comprehensive Cancer CenterSWOG Cancer Research NetworkThe University of Texas MD Anderson Cancer CenterUniversity of Southern California
DR

About

David R. Gandara is an author at University of California, Davis specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

56

246

19.9K

2

Health Sciences

28

78

7.3K

3

Engineering

7

7

671

4

Education

1

1

20

5

Nursing

1

1

115

David R. Gandara

×

395

Publications

46.2K

Citations

88

H-Index

YearCitations

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp,

The Lancet

2016

4.7K

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel,

Journal of Clinical Oncology

2008

3.2K

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Timothy Winton, Robert B. Livingston, David C. Johnson,

New England Journal of Medicine

2005

1.8K

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

Kathy S. Albain, Ruth Swann, Valerie W. Rusch,

The Lancet

2009

1.5K

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard,

The Lancet Oncology

2015

1.4K

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr,

Journal of Clinical Oncology

2000

1.4K

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz,

Nature Medicine

2018

1.2K

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

Karen Kelly, John Crowley, Paul A. Bunn,

Journal of Clinical Oncology

2001

1.1K

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

Kathy S. Albain, Valerie W. Rusch, John J. Crowley,

Journal of Clinical Oncology

1995

857

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Reginald V. Lord, Jan Brabender, David R. Gandara,

PubMed

2002

671

Page 1